The US Food and Drug Administration (FDA) has authorized the Jynneous vaccine of Bavarian Nordic for emergency use through intradermal injection in individuals aged 18 years and older, who are determined to be at high risk of monkeypox disease.
The authorization from the US Food and Drug Administration (FDA) will also increase the total number of doses available for use by around five-fold. It also allows individuals, who are younger than 18 years to receive the vaccine by subcutaneous injection if they are determined to be at high risk of monkeypox disease.
Robert Califf, US FDA commissioner, said in recent weeks that the monkeypox disease has continued to spread at a rate that has made it clear that their current vaccine supply will not meet the current demand of the market.
This move follows the decision of the administration of Joe Biden, president of the United States, to allow the FDA commissioner to grant emergency use authorization for the monkeypox vaccines.
For those adult aged 18 and older, monkeypox infection has been determined to be at high risk, and the authorization allows for a fraction of the Jynneos dose to be administered between the layers of the skin. The US FDA also said the two doses of the vaccine are given four weeks apart and will still be needed.